Correction: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Correction: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis

Published:2023-07-26 Issue:1 Volume:21 Page:
ISSN:1477-7827
Container-title:Reproductive Biology and Endocrinology
language:en
Short-container-title:Reprod Biol Endocrinol

Author:

Venetis Christos A.,Helwig Christoph,Mol Ben W.,Chua Su Jen,Longobardi Salvatore,Orvieto Raoul,Lispi Monica,Storr Ashleigh,D’Hooghe Thomas

Publisher

Springer Science and Business Media LLC

Subject

Developmental Biology,Endocrinology,Reproductive Medicine,Obstetrics and Gynecology

Link

https://link.springer.com/content/pdf/10.1186/s12958-023-01114-5.pdf

Reference2 articles.

1. Chua SJ, Mol BW, Longobardi S, et al. Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2021;19:51. https://doi.org/10.1186/s12958-021-00727-y.

2. Hu L, et al. Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing in vitro fertilization-embryo transfer. Aging (Albany NY). 2020;12(6):4918–30.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preface: Health economics and outcomes research in reproductive medicine: Methods and comparative effectiveness of treatment protocols;Best Practice & Research Clinical Obstetrics & Gynaecology;2024-02